-
Posted by
Two Blokes Jun 9 -
Filed in
Stock
-
2 views
Sanara MedTech's surgical revenue grew 26% year-over-year in Q1, with a gross margin of 92%. Surgical adjusted EBITDA was $2.7 million in Q1, while THP correspondingly posted a loss of $2 million. High debt levels and elevated interest expenses are key risks, along with the uncertainty surrounding the commercialization of THP.